Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 17/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 11/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282253 | 0.90 | NPBWR1 (0.59) | NPBWR1MCHR1NPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL4779571 | 0.89 | NPBWR1 (0.58) | NPBWR1MCHR1NPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL14005327 | 0.89 | NPBWR1 (0.61) | NPBWR1MCHR1NPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL14282260 | 0.89 | NPBWR1 (0.58) | NPBWR1MCHR1NPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL4937351 | 0.88 | NPBWR1 (0.57) | NPBWR1MCHR1NPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL4670320 | 0.88 | NPBWR1 (0.57) | NPBWR1MCHR1NPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL4672093 | 0.87 | NPBWR1 (0.56) | NPBWR1MCHR1NPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL4675684 | 0.87 | NPBWR1 (0.56) | NPBWR1MCHR1NPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL4937342 | 0.87 | NPBWR1 (0.56) | NPBWR1MCHR1NPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL4673816 | 0.87 | NPBWR1 (0.56) | NPBWR1MCHR1NPSR1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497269-B1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1497269-B1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-05 | — | — | US | disclosed |
| EP-1497269-A1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | Bayer HealthCare AG (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003097612-A1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | PIR, TPMT, PNPO | NPBWR1 4199/4885MCHR1 4400/4885NPSR1 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.